enGene CEO to Discuss Pipeline Progress at Guggenheim Biotech Summit
Event summary
- enGene CEO Ron Cooper to participate in fireside chat on February 11, 2026, at 2:30 p.m. ET
- Webcast available on enGene's investor relations page for 90 days
- Focus on detalimogene voraplasmid (detalimogene) for NMIBC in Phase 2 LEGEND trial
- DDX platform enables mucosal tissue delivery of genetic medicines
The big picture
enGene's participation in Guggenheim's biotech summit comes as non-viral genetic medicine platforms gain traction. The company's focus on mucosal delivery positions it in a niche segment of the broader gene therapy market, where traditional viral vectors face delivery challenges. Success in NMIBC could validate enGene's DDX platform for other high-need indications.
What we're watching
- Clinical Milestones
- How the LEGEND trial's pivotal cohort data will impact detalimogene's regulatory path
- Market Positioning
- Whether enGene can differentiate its non-viral approach in competitive NMIBC space
- Investor Sentiment
- The pace at which enGene can translate platform technology into diversified pipeline
Related topics